2,3-dihydro-1-(4-piperidinyl)-1H-indole monohydrochloride | 181525-35-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2,3-dihydro-1-(4-piperidinyl)-1H-indole monohydrochloride
• 英文别名: 1-(4-piperidinyl)-2,3-dihydro-1H-indole hydrochloride；1-(piperidin-4-yl)indoline HCl salt；1-piperidin-4-yl-2,3-dihydroindole;hydrochloride
• CAS: 181525-35-9
• 化学式: C₁₃H₁₈N₂*ClH
• 分子量: 238.76
• InChiKey: WIZISJFELKDUSK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.22
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  15.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,3-dihydro-1-(4-piperidinyl)-1H-indole monohydrochloride 在 四(三苯基膦)钯 、 potassium carbonate 、 三乙胺 作用下， 以 1,4-二氧六环 、 水 、 二甲基亚砜 为溶剂， 反应 10.0h， 生成 1-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)indoline
  参考文献：
  名称：

  4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable stearoyl-CoA desaturase-1 (SCD1) inhibitors: Part 2. Pyridazine-based analogs

  摘要：

  Design, synthesis, and biological evaluation of pyridazine-based, 4-bicyclic heteroaryl-piperidine derivatives as potent stearoyl-CoA desaturase-1 (SCD1) inhibitors are described. In a chronic study of selected analog (3e) in Zucker fa/fa (ZF) rat, dose-dependent decrease of body weight gain and plasma fatty acid desaturation index (DI) in both C16 and C18 are also demonstrated. The results indicate that the plasma fatty acid DI may serve as an indicator for direct target engagement and biomarker for SCD1 inhibition. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.075
• 作为产物：
  描述：

  4-吲哚啉-1-哌啶-1-羧酸叔丁酯 在 盐酸 、 甲醇 作用下， 以 1,4-二氧六环 为溶剂， 反应 6.0h， 以100%的产率得到2,3-dihydro-1-(4-piperidinyl)-1H-indole monohydrochloride
  参考文献：
  名称：

  [EN] 1-PIPERIDINYL-6-PIPERIDINYLSULFONYLINDOLES AS 5-HT (2B) RECEPTOR ANTAGONISTS
  [FR] 1-PIPERIDINYL-6-PIPERIDINYLSULFONYLINDOLES UTILISÉS COMME ANTAGONISTES DU RÉCEPTEUR 5-HT (2B)

  摘要：

  本发明涉及新型吲哚衍生物，其结合到5-HT2B受体并能够干扰5-羟色胺（5-HT）在5-HT2B受体上的作用；其制备过程；包含它们的制药组合物；以及在治疗中使用这些化合物的用途。

  公开号：

  WO2009016225A1

文献信息

• 4-(1H-indol-1-yl)-1-piperidinyl derivatives
  申请人：Janssen Pharmaceutica, N.V.

  公开号：US05919788A1

  公开（公告）日：1999-07-06

  The present invention concerns the compounds of formula ##STR1## the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein the dashed line designates an optional bond; R.sup.1 and R.sup.2 are each independently hydrogen, halogen, C.sub.1-6 alkyl or C.sub.1-6 alkyloxy; R.sup.3 and R.sup.4 are each independently hydrogen, C.sub.1-6 alkyl, phenyl or phenyl substituted with one, two or three substituents selected from halo, hydroxy, nitro, cyano, trifluoromethyl, C.sub.1-6 alkyl, C.sub.1-6 alkyloxy, C.sub.1-6 alkylthio, mercapto, amino, mono- and di(C.sub.1-6 alkyl)-amino, carboxyl, C.sub.1-6 alkyloxycarbonyl and C.sub.1-6 alkylcarbonyl; Alk is C.sub.1-4 alkanediyl; D is a pyrimidinone, piperidone or a benzimidozolidinone; having antipsychotic activity; their preparation, compositions containing them and their use as a medicine.

  本发明涉及公式##STR1##的化合物，其药学上可接受的加成盐和立体化学异构体，其中虚线表示可选键；R.sup.1和R.sup.2各自独立地为氢，卤素，C.sub.1-6烷基或C.sub.1-6烷氧基；R.sup.3和R.sup.4各自独立地为氢，C.sub.1-6烷基，苯基或苯基上取代有一，两或三种取自卤素，羟基，硝基，氰基，三氟甲基，C.sub.1-6烷基，C.sub.1-6烷氧基，C.sub.1-6烷硫基，巯基，氨基，单和双(C.sub.1-6烷基)-氨基，羧基，C.sub.1-6烷氧羰基和C.sub.1-6烷基羰基的取代基；Alk为C.sub.1-4烷二基；D为嘧啶酮，哌啶酮或苯并咪唑啉酮；具有抗精神病活性；它们的制备，含有它们的组合物以及它们作为药物的用途。
• Substituted piperidinyl-pyridazinyl derivatives useful as SCD 1 inhibitors
  申请人：Janssen Pharmaceutica NV

  公开号：US09102669B2

  公开（公告）日：2015-08-11

  The present invention is directed to novel piperidinyl-pyridazinyl derivatives, pharmaceutical compositions containing them and their use as inhibitors of SCD1, useful in the treatment of obesity, type-II diabetes and other related metabolic disorders.

  本发明涉及新型哌啶基-吡啶嗪衍生物、含有它们的药物组合物以及它们作为SCD1抑制剂的用途，可用于治疗肥胖症、2型糖尿病和其他相关代谢性疾病。
• SUBSTITUTED PIPERIDINYL-CARBOXAMIDE DERIVATIVES USEFUL AS SCD 1 INHIBITORS
  申请人：Janssen Pharmaceutica NV

  公开号：US20140364393A1

  公开（公告）日：2014-12-11

  The present invention is directed to novel piperidinyl-carboxamide derivatives, pharmaceutical compositions containing them and their use as inhibitors of SCD1, useful in the treatment of obesity, type-II diabetes and other related metabolic disorders.

  本发明涉及新型哌啶基-羧酰胺衍生物、包含它们的制药组合物以及它们作为SCD1抑制剂的用途，用于治疗肥胖症、2型糖尿病和其他相关代谢性疾病。
• SUBSTITUTED PIPERIDINYL-PYRIDAZINYL DERIVATIVES USEFUL AS SCD 1 INHIBITORS
  申请人：Janssen Pharmaceutica NV

  公开号：US20140371220A1

  公开（公告）日：2014-12-18

  The present invention is directed to novel piperidinyl-pyridazinyl derivatives, pharmaceutical compositions containing them and their use as inhibitors of SCD1, useful in the treatment of obesity, type-II diabetes and other related metabolic disorders.

  本发明涉及新型哌啶基-吡啶嗪衍生物、包含它们的药物组合物以及它们作为SCD1抑制剂的用途，适用于治疗肥胖症、2型糖尿病和其他相关代谢性疾病。
• 4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable Stearoyl-CoA desaturase-1 (SCD1) inhibitors. Part 1: Urea-based analogs
  作者：Shyh-Ming Yang、Yuting Tang、Rui Zhang、Huajun Lu、Gee-Hong Kuo、Michael D. Gaul、Yaxin Li、George Ho、James G. Conway、Yin Liang、James M. Lenhard、Keith T. Demarest、William V. Murray

  DOI：10.1016/j.bmcl.2013.09.096

  日期：2013.12

  A new series of urea-based, 4-bicyclic heteroaryl-piperidine derivatives as potent SCD1 inhibitors is described. The structure-activity relationships focused on bicyclic heteroarenes and aminothiazole-urea portions are discussed. A trend of dose-dependent decrease in body weight gain in diet-induced obese (DIO) mice is also demonstrated. (C) 2013 Elsevier Ltd. All rights reserved.